Gilead Sciences | GILD - Sales Revenues

Stock Price
139.94
Daily Change
0.57 0.41%
Monthly
-6.73%
Yearly
25.07%
Q2 Forecast
130.22

Gilead Sciences reported $7.93B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
ALKERMES USD 384.5M 9.7M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
Incyte USD 1.51B 140M Dec/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025